HECTD4

Across TCGA pan-cancer cohorts, HECTD4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HECTD4 data layer compared with 22 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HECTD4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HECTD4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where HECTD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.433	0.816	.002	22	view →
LSCC	OS	Tertile	All	0.919	0.715	.015	14	view →
LUAD	OS	Tertile	All	0.502	0.848	.014	8	view →
GBM	DFS	Quartile	All	0.928	0.655	<.001	6	view →
CCRCC	OS	Quartile	III,IV	0.380	0.850	.011	1	view →
HNSC	DFS	Median	IV	1.000	0.927	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HECTD4–PDAC (OS)

Open the PDAC breakdown →